{"success":true,"data":{"pressRelease":{"id":"157096","rtpr_id":"nGNX5VXp1h-20260930","ticker":"CELU","exchange":"NASDAQ","all_tickers":["CELU"],"title":"Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner","author":"Globe Newswire","published_at":"2026-09-30T15:57:53.100Z","article_body":"FLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celularity Inc.\n(Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused\nregenerative and cellular medicine company pioneering placental-derived\ncellular therapies, today highlighted continued progress at Fontaine Vitale, a\nregenerative medicine and wellness center being developed in the Sanur Special\nEconomic Zone (“Sanur SEZ”) in Bali, Indonesia, in anticipation of its\ngrand opening in the first quarter of 2027.\n\nDeveloped by Genting Berhad and its Indonesian partners with strategic\ncollaboration and input from Celularity, Fontaine Vitale is designed to serve\nlocal and international patients seeking advanced wellness, aesthetics,\nlongevity and regenerative medicine services at a four-story facility of an\napproximately 172,000-square feet with extensive landscaped gardens, Balinese\ninspired design and modern amenities. Learn more at\nhttps://fontainevitale.com/.\n\nFontaine Vitale is expected to be the first facility in the ASEAN region to\noffer placenta-derived allogeneic stem cell therapy, leveraging Celularity’s\ntechnology and products manufactured at the Company’s cGMP research and\nmanufacturing facility in Florham Park, New Jersey. Celularity expects to\nsupply its placenta-derived platform of products to Fontaine Vitale, subject\nto final commercial arrangements, applicable regulatory authorizations,\ntreatment protocols and market conditions.\n\nNew Market and Revenue Opportunity\n\nFontaine Vitale is designed to accommodate physician-directed treatments for\nlocal and international patients. As the facility builds utilization following\nits opening, Celularity believes it represents a significant new market and\nrevenue opportunity for the Company.\n\n“The excitement building around the anticipated grand opening of Fontaine\nVitale is extraordinary, and the facility coming up looks amazing,” said\nRobert J. Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer\nof Celularity. “For Celularity, Fontaine Vitale represents a platform for\nintroducing our placenta-derived cellular technology to patients throughout\nIndonesia and the broader Asia-Pacific region.”\n\nDr. Hariri continued, “Importantly, we believe Celularity is well positioned\nto support the growth of Fontaine Vitale making it a leading destination for\nnovel regenerative therapeutic products. Together with Genting, we aspire to\nbuild a model for regenerative longevity that brings scientific innovation\ncloser to patients and helps shape how these therapies are responsibly\ndeployed around the world.”\n\nFontaine Vitale is expected to initially offer physician-directed services\nfocused on wellness and resilience, anti-aging and vitality, musculoskeletal\nand mobility support, and aesthetic and skin rejuvenation. The facility is\nlocated within the Sanur SEZ, Indonesia’s first medical-tourism special\neconomic zone, which is being developed as an integrated international\nhealthcare, wellness and hospitality destination.\n\nAbout Celularity\n\nCelularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and\ncellular medicine company developing and manufacturing allogeneic and\nautologous cell therapies derived from the postpartum placenta. Celularity\ndraws on the placenta’s unique biology, immunologic properties and scalable\navailability to develop therapeutic solutions targeting fundamental mechanisms\nof aging and age-related disease. Its cellular therapy portfolio includes\ncenplacel-L, its investigational placenta-derived allogeneic cell therapy, and\nother investigational cellular therapies. Celularity is headquartered in\nFlorham Park, New Jersey, where it operates a purpose-built cGMP research and\nmanufacturing facility supporting the development and manufacture of cellular\ntherapies, advanced biomaterials and other longevity and wellness-focused\nproducts.\n\nFor more information, please visit: www.celularity.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\napplicable federal securities laws. These statements include, without\nlimitation, statements regarding the anticipated January 2027 opening and\ncommencement of operations at Fontaine Vitale; its planned services,\ncapabilities and potential position in the ASEAN regenerative medicine market;\nCelularity’s anticipated supply of cellular products and the completion of\nrelated commercial arrangements; expected patient demand, facility utilization\nand growth; potential market and revenue opportunities; and the expansion of\naccess to Celularity’s technology and products in Indonesia and the broader\nAsia-Pacific region. These statements are based on management’s current\nexpectations and assumptions and are not guarantees of future performance.\n\nActual results could differ materially due to risks and uncertainties,\nincluding delays in completing, licensing or opening Fontaine Vitale; the\nability to obtain and maintain applicable authorizations for the importation,\nsupply and use of cellular products in Indonesia; changes in laws, regulations\nor policies governing regenerative medicine, medical tourism or the Sanur\nSpecial Economic Zone; the ability to finalize and implement commercial\narrangements and treatment protocols; the performance of Genting, Fontaine\nVitale and other third parties on which the opportunity depends; the timing\nand extent of physician and patient adoption, international patient travel and\nfacility utilization; actual order volumes, pricing and payment terms;\nmanufacturing capacity, product quality, release requirements, shelf life and\ncross-border transport and storage; clinical safety and efficacy uncertainties\nassociated with investigational cellular therapies; and Celularity’s ability\nto obtain sufficient funding, meet its obligations and maintain the personnel\nand infrastructure necessary to support these activities. The anticipated\nopening of Fontaine Vitale does not assure that Celularity will receive\nproduct orders or generate revenue, and any revenue may be delayed or lower\nthan anticipated.\n\nAdditional risks are described under “Risk Factors” and elsewhere in\nCelularity’s filings with the Securities and Exchange Commission, including\nits most recent Annual Report on Form 10-K and subsequent Quarterly Reports on\nForm 10-Q and Current Reports on Form 8-K. Forward-looking statements speak\nonly as of the date of this release, and readers should not place undue\nreliance on them. Except as required by law, Celularity undertakes no\nobligation to publicly update or revise any forward-looking statement, whether\nas a result of new information, future events or otherwise.\n\nInvestor and Media Contact:\ninfo@celularity.com\n\n\n\nGlobeNewswire, Inc. 2026","article_body_html":"","raw_payload":{"data":{"id":"nGNX5VXp1h-20260930","title":"Celularity Highlights Anticipated Quarter One 2027 Opening of Fontaine Vitale as Strategic Partner","author":"Globe Newswire","ticker":"CELU","created":"2026-09-30T15:57:53.100Z","tickers":["CELU"],"exchange":"NASDAQ","article_body":"FLORHAM PARK, N.J., Sept. 30, 2026 (GLOBE NEWSWIRE) -- Celularity Inc.\n(Nasdaq: CELU) (“Celularity” or the “Company”), a longevity-focused\nregenerative and cellular medicine company pioneering placental-derived\ncellular therapies, today highlighted continued progress at Fontaine Vitale, a\nregenerative medicine and wellness center being developed in the Sanur Special\nEconomic Zone (“Sanur SEZ”) in Bali, Indonesia, in anticipation of its\ngrand opening in the first quarter of 2027.\n\nDeveloped by Genting Berhad and its Indonesian partners with strategic\ncollaboration and input from Celularity, Fontaine Vitale is designed to serve\nlocal and international patients seeking advanced wellness, aesthetics,\nlongevity and regenerative medicine services at a four-story facility of an\napproximately 172,000-square feet with extensive landscaped gardens, Balinese\ninspired design and modern amenities. Learn more at\nhttps://fontainevitale.com/.\n\nFontaine Vitale is expected to be the first facility in the ASEAN region to\noffer placenta-derived allogeneic stem cell therapy, leveraging Celularity’s\ntechnology and products manufactured at the Company’s cGMP research and\nmanufacturing facility in Florham Park, New Jersey. Celularity expects to\nsupply its placenta-derived platform of products to Fontaine Vitale, subject\nto final commercial arrangements, applicable regulatory authorizations,\ntreatment protocols and market conditions.\n\nNew Market and Revenue Opportunity\n\nFontaine Vitale is designed to accommodate physician-directed treatments for\nlocal and international patients. As the facility builds utilization following\nits opening, Celularity believes it represents a significant new market and\nrevenue opportunity for the Company.\n\n“The excitement building around the anticipated grand opening of Fontaine\nVitale is extraordinary, and the facility coming up looks amazing,” said\nRobert J. Hariri, M.D., Ph.D., Founder, Chairman and Chief Executive Officer\nof Celularity. “For Celularity, Fontaine Vitale represents a platform for\nintroducing our placenta-derived cellular technology to patients throughout\nIndonesia and the broader Asia-Pacific region.”\n\nDr. Hariri continued, “Importantly, we believe Celularity is well positioned\nto support the growth of Fontaine Vitale making it a leading destination for\nnovel regenerative therapeutic products. Together with Genting, we aspire to\nbuild a model for regenerative longevity that brings scientific innovation\ncloser to patients and helps shape how these therapies are responsibly\ndeployed around the world.”\n\nFontaine Vitale is expected to initially offer physician-directed services\nfocused on wellness and resilience, anti-aging and vitality, musculoskeletal\nand mobility support, and aesthetic and skin rejuvenation. The facility is\nlocated within the Sanur SEZ, Indonesia’s first medical-tourism special\neconomic zone, which is being developed as an integrated international\nhealthcare, wellness and hospitality destination.\n\nAbout Celularity\n\nCelularity Inc. (Nasdaq: CELU) is a longevity-focused regenerative and\ncellular medicine company developing and manufacturing allogeneic and\nautologous cell therapies derived from the postpartum placenta. Celularity\ndraws on the placenta’s unique biology, immunologic properties and scalable\navailability to develop therapeutic solutions targeting fundamental mechanisms\nof aging and age-related disease. Its cellular therapy portfolio includes\ncenplacel-L, its investigational placenta-derived allogeneic cell therapy, and\nother investigational cellular therapies. Celularity is headquartered in\nFlorham Park, New Jersey, where it operates a purpose-built cGMP research and\nmanufacturing facility supporting the development and manufacture of cellular\ntherapies, advanced biomaterials and other longevity and wellness-focused\nproducts.\n\nFor more information, please visit: www.celularity.com.\n\nForward-Looking Statements\n\nThis press release contains forward-looking statements within the meaning of\napplicable federal securities laws. These statements include, without\nlimitation, statements regarding the anticipated January 2027 opening and\ncommencement of operations at Fontaine Vitale; its planned services,\ncapabilities and potential position in the ASEAN regenerative medicine market;\nCelularity’s anticipated supply of cellular products and the completion of\nrelated commercial arrangements; expected patient demand, facility utilization\nand growth; potential market and revenue opportunities; and the expansion of\naccess to Celularity’s technology and products in Indonesia and the broader\nAsia-Pacific region. These statements are based on management’s current\nexpectations and assumptions and are not guarantees of future performance.\n\nActual results could differ materially due to risks and uncertainties,\nincluding delays in completing, licensing or opening Fontaine Vitale; the\nability to obtain and maintain applicable authorizations for the importation,\nsupply and use of cellular products in Indonesia; changes in laws, regulations\nor policies governing regenerative medicine, medical tourism or the Sanur\nSpecial Economic Zone; the ability to finalize and implement commercial\narrangements and treatment protocols; the performance of Genting, Fontaine\nVitale and other third parties on which the opportunity depends; the timing\nand extent of physician and patient adoption, international patient travel and\nfacility utilization; actual order volumes, pricing and payment terms;\nmanufacturing capacity, product quality, release requirements, shelf life and\ncross-border transport and storage; clinical safety and efficacy uncertainties\nassociated with investigational cellular therapies; and Celularity’s ability\nto obtain sufficient funding, meet its obligations and maintain the personnel\nand infrastructure necessary to support these activities. The anticipated\nopening of Fontaine Vitale does not assure that Celularity will receive\nproduct orders or generate revenue, and any revenue may be delayed or lower\nthan anticipated.\n\nAdditional risks are described under “Risk Factors” and elsewhere in\nCelularity’s filings with the Securities and Exchange Commission, including\nits most recent Annual Report on Form 10-K and subsequent Quarterly Reports on\nForm 10-Q and Current Reports on Form 8-K. Forward-looking statements speak\nonly as of the date of this release, and readers should not place undue\nreliance on them. Except as required by law, Celularity undertakes no\nobligation to publicly update or revise any forward-looking statement, whether\nas a result of new information, future events or otherwise.\n\nInvestor and Media Contact:\ninfo@celularity.com\n\n\n\nGlobeNewswire, Inc. 2026"},"type":"article","timestamp":"2026-09-30T15:57:53.154310175Z","server_sent_at_ms":1790783873154},"received_at":"2026-09-30T15:57:53.208Z","source_url":null},"analysis":{"id":"145771","press_release_id":"157096","analysis_json":{"industry":{"label":"Pharmaceuticals, Biotechnology & Life Sciences","sector":"Health Care"},"redFlags":["no firm commercial agreement disclosed; supply subject to 'final commercial arrangements'","revenue contingent on regulatory authorizations and facility utilization; company explicitly warns opening does not assure orders or revenue","forward-looking statement flags funding risk to support these activities"],"eventType":"operations_update","narrative":"Celularity highlighted progress at Fontaine Vitale, a 172,000-square-foot regenerative medicine and wellness center in Bali's Sanur Special Economic Zone, with grand opening anticipated in Q1 2027.\n\nThe facility, developed by Genting Berhad with Celularity collaboration, is expected to be the first in ASEAN to offer placenta-derived allogeneic stem cell therapy using Celularity products manufactured in Florham Park, New Jersey.\n\nCelularity frames the facility as a new market and revenue opportunity, but product supply remains subject to final commercial arrangements and regulatory authorizations, and no orders or revenue are assured.","sentiment":"bullish","agentHooks":{"shouldPost":false,"suggestedAngle":"Speculative APAC commercialization optionality for CELU's placenta-derived platform via Genting's Bali wellness facility -- early-stage, no firm revenue."},"keyFigures":{"customDimensions":{"expected_opening":"Q1 2027","facility_size_sqft":172000}},"quotedText":"Fontaine Vitale represents a platform for introducing our placenta-derived cellular technology to patients throughout Indonesia and the broader Asia-Pacific region.","namedEntities":{"people":[{"name":"Robert J. Hariri, M.D., Ph.D.","role":"Founder, Chairman and CEO of Celularity"}],"products":["Fontaine Vitale","cenplacel-L"],"companies":[{"name":"Celularity Inc.","ticker":"CELU","relationship":"filer"},{"name":"Genting Berhad","relationship":"partner/developer"}],"dollarAmounts":[]},"materialImpact":{"score":2,"reasoning":"Promotional progress update on a third-party wellness facility Celularity hopes to supply, with opening not expected until Q1 2027 and all commercial arrangements still subject to finalization. No revenue, orders, or firm contract disclosed."},"tickerRelevance":{"others":[],"primary":"CELU"},"globalImportance":12,"audienceRelevance":15,"eventTypeSecondary":["partnership"],"importanceComponents":{"tickerTier":"micro-cap","eventGravity":"promotional progress update, no firm contract","revenueCertainty":"low"}},"event_type":"operations_update","event_type_secondary":["partnership"],"sentiment":"bullish","material_impact_score":2,"narrative":"Celularity highlighted progress at Fontaine Vitale, a 172,000-square-foot regenerative medicine and wellness center in Bali's Sanur Special Economic Zone, with grand opening anticipated in Q1 2027.\n\nThe facility, developed by Genting Berhad with Celularity collaboration, is expected to be the first in ASEAN to offer placenta-derived allogeneic stem cell therapy using Celularity products manufactured in Florham Park, New Jersey.\n\nCelularity frames the facility as a new market and revenue opportunity, but product supply remains subject to final commercial arrangements and regulatory authorizations, and no orders or revenue are assured.","key_figures":{"customDimensions":{"expected_opening":"Q1 2027","facility_size_sqft":172000}},"named_entities":{"people":[{"name":"Robert J. Hariri, M.D., Ph.D.","role":"Founder, Chairman and CEO of Celularity"}],"products":["Fontaine Vitale","cenplacel-L"],"companies":[{"name":"Celularity Inc.","ticker":"CELU","relationship":"filer"},{"name":"Genting Berhad","relationship":"partner/developer"}],"dollarAmounts":[]},"model_name":"glm-5.3-flashx","prompt_hash":"sha256:727b4b9429a443af","schema_hash":"sha256:05005c02d9cffac9","created_at":"2026-09-30T15:57:59.024Z","global_importance":12,"audience_relevance":15,"importance_components":{"tickerTier":"micro-cap","eventGravity":"promotional progress update, no firm contract","revenueCertainty":"low"}},"durationMs":5809,"modelName":"glm-5.3-flashx"}}